A friend texted me last month, mid-rant: her scale is down one pound this week, but every headline she’s seen promises 15%. “Is mine broken?” she asked. It’s not broken. Nobody handed her the division problem, so I’m about to hand it to you.
Here’s the math nobody shows you. In the big trial of semaglutide 2.4 mg (that’s Wegovy, the FDA-approved weight-loss version of the drug), people lost an average of 14.9% of their body weight over 68 weeks. Do the division: 14.9 divided by 68 is roughly 0.2% of your body weight per week. For the trial’s typical participant, who weighed about 230 pounds, that’s somewhere between 1 and 2 pounds a week.
So that headline “15%!” is a 68-week average, not a weekly rate. That sentence is the whole article, honestly. Everything else is just the shape of the curve and the things that change your personal number.
Key Takeaways
Semaglutide 2.4 mg averaged 14.9% body weight loss over 68 weeks in STEP 1, which works out to roughly 0.2% of body weight (about 1-2 lb) per week, not the sprint the headlines imply.
Loss is slow through week 16 while the dose ramps up, fastest in the middle, and plateaus around week 60 but holds, while people who stopped the drug regained about 7% of their body weight.
Type 2 diabetes, staying on a lower dose, and less support all lower the expected number; the same drug averaged 9.6%, 14.9%, and 16.0% across three different trials.
Table of Contents
Why the first month on Wegovy looks empty
No trial reports a month-one weight-loss endpoint, so there’s no honest “you’ll lose X pounds in 4 weeks” number to give you. The real answer is the dosing schedule, because for the first four months, the drug is still warming up.
Here’s the ladder, called titration. That’s the deliberate ramp-up where you start at a dose too small to do much weight-loss work, so your body can handle the drug without spending every day nauseated:
- 0.25 mg
- 0.5 mg
- 1.0 mg
- 1.7 mg
- 2.4 mg (the full maintenance dose, reached by week 16)
A step every 4 weeks. The early doses exist to prevent nausea, not to melt pounds. Meanwhile the drug itself takes time to build up: it peaks in your blood about 3 days after each shot, doesn’t reach steady levels until around week 5, and has a half-life of about a week. Translation: it takes weeks to accumulate, so judging your results at week two is like judging a slow cooker before you’ve plugged it in.
So if the scale barely moves in month one, that’s not the drug failing. It’s a ramp, not a line. One small mercy: injection site doesn’t change how much of the drug you absorb, belly, thigh, or arm all work the same, and rotating sites is fine.
I know the flat early weeks are discouraging. You finally got the prescription, you’re doing everything right, and the number just sits there. That disappointment is real and normal. It’s also, based on the trial design, expected.
Semaglutide weight loss timeline: the curve, not a line
The weekly rate changes depending on when you ask. It’s slow through the 16-week ramp-up, fastest in the middle months, and it levels off near week 60. That’s the actual shape of the curve, and it matters because it means a “slow week” means different things at different points.
The best evidence for the back end comes from the two-year trial. Fair warning: it’s a smaller group, about 300 people, not the nearly 2,000 in the main study. Those folks lost 15.2% versus 2.6% on placebo over 104 weeks, and the key part is what happened between year one and year two: the loss held at about 15%. It stopped dropping.
It didn’t bounce back. The plateau around week 60 is the treatment working, not failing.
And then there’s the question everybody asks quietly: what happens the week I stop? The withdrawal trial actually tested it. People who switched off the drug regained about 7% of their body weight, while the people who kept taking it lost another 8% during the same stretch. Those are the only hard numbers we have on the stop-week question, and they’re blunt.
This is why doctors talk about obesity as a chronic condition, the same way they’d talk about blood pressure meds. You don’t quit the blood pressure pill when the number looks good. This is knowledge, not doom. Go in with eyes open.
The direct answer: weekly and monthly numbers from the STEP trials
Roughly 0.2 to 0.3% of your body weight per week, which is about 0.5 to 1 lb for a 200-lb person, once you’re at the full maintenance dose. That’s the honest steady-state answer, with the caveat that week-to-week loss is not linear. Some weeks will be zero. Some will surprise you.
The main trial, STEP 1, deserves a quick trust line: nearly 2,000 people across 16 countries in a real randomized controlled trial. The participants were mostly women, average age 46, average starting weight 105.3 kg (about 232 lb). On the drug they lost 14.9% over 68 weeks; on placebo, 2.4%. That gap is the story.
Now the number most articles skip: 86.4% of the drug group lost at least 5% of their body weight. Which means roughly one in seven didn’t, even after 68 weeks on the full dose. The average is a distribution, not a promise, and if you’re in the unlucky seventh, you’re not broken.
The two-year data comes from STEP 5: over 104 weeks, 304 people on the drug lost 15.2% versus 2.6% on placebo (a treatment difference of 12.6 percentage points, 95% CI -15.3 to -9.8, p<0.0001), 77.1% hit at least 5% versus 34.4% on placebo (OR 5.0), and 92.8% stayed in the trial the whole two years. Breaking the responders into a ladder:
- 5% or more lost: 77%
- 10% or more: 62%
- 15% or more: 52%
- 20% or more: 36%
So even the “modest” outcome, 5% down and holding, was the majority experience over two years. If you weigh 200 lb, 5% is 10 lb. Not a movie montage. Real, and clinically meaningful, which we’ll get to.
What moves your number: dose, diabetes, and lifestyle support
Three things shift your expected weekly loss: your diabetes status, your dose, and how much support you’re getting. Here’s the punchline that makes the point better than any single stat: the same drug produced 9.6%, 14.9%, and 16.0% average losses across three trials. The drug was constant. The people and the circumstances weren’t.
Diabetes lowers it
If you have type 2 diabetes, your expected number is smaller, and you deserve that stated plainly instead of having to do mental adjustment on the headline. In the diabetes trial, about 1,200 adults across 68 weeks, the drug group lost 9.6% versus 3.4% on placebo. Real, meaningful, just less than the non-diabetes trials. Still the majority: most participants hit at least 5%.
One monitoring note: in that trial, retinopathy (eye complications) showed up in 4% of the drug group versus 2.7% on placebo. Rapid blood-sugar improvement can temporarily worsen eye issues; it’s a known pattern. Worth a conversation with your doctor if you have any retinopathy history.
Dose matters
In a dose-finding trial of about 950 people over a year, loss climbed with dose: around 6% at the lowest tested dose, nearly 14% at the highest. And in the diabetes trial, the 1.0 mg dose (the Ozempic dose) only managed 7%. So, How Long Does It Take to Lose 20 lbs on Ozempic? It depends on the dose escalations, which is why the slow ramp-up to 2.4 mg is deliberate, not your doctor being stingy, and why patience during the escalation months pays off. It is not a suggestion to take more than prescribed.
Support raises it
The intensive-lifestyle trial stacked the shot on top of a strict low-calorie diet, activity building to 200 minutes a week, and about 30 visits with a dietitian. Result: 16.0% average loss. And I’ll be honest with you: that’s a LOT. If you’re curious, here’s a friendly How Do Weight Loss Injections Work? explainer that breaks it all down in plain language. Most real lives, mine included, will never be arranged like a clinical trial, and that’s okay.
The lesson isn’t “try harder.” It’s that extra help stacks results, and whatever support you can realistically get moves the number in the right direction.
One thing worth knowing about what the approval assumes: diet and exercise changes were required in every trial arm, including the placebo groups. The drug works alongside those changes, not instead of them. And about that 150-minutes-a-week exercise guidance? It can be chunked.
Ten minutes here, a stroller walk there, soccer-practice laps around the field. It counts.
Wegovy vs Ozempic vs Zepbound vs Saxenda: which injection loses more?
In the one direct head-to-head trial, weekly semaglutide 2.4 mg beat daily liraglutide: 15.8% versus 6.4% over 68 weeks, and about three times as many people hit the 10% milestone (71% versus 26%), one reason semaglutide telehealth programs have drawn attention from those who’ve struggled to see results through boot camps and strict macro-counting alone.
First, the naming tangle, because it confuses everyone. Ozempic is the same drug as Wegovy at a lower dose, approved for diabetes. Saxenda is the older daily shot (liraglutide), and then there’s tirzepatide, a different drug entirely, covered in this Mounjaro Weight Loss Injections: What You Need to Know guide. Same drug family, different doses and schedules.
The rest of the scoreboard comes from separate trials, so no crowning a champion with certainty, but here’s the honest tiering:
- Semaglutide 2.4 mg (Wegovy): ~15% over 68 weeks, the best-tested number
- The diabetes-dose semaglutide 1.0 mg (Ozempic): only 7%
- Tirzepatide (Zepbound/Mounjaro): averages around 20%
- Wegovy 7.2 mg (the higher dose): ~19%, about 47 lb, in a 72-week study, manufacturer-reported, so hold it a little loosely
- Older meds, each from its own trial: liraglutide averaged 8.0% with 63.2% hitting 5%; phentermine/topiramate ranged 7.8% to 9.8%; bupropion/naltrexone managed 6.1% with 48% hitting 5%; orlistat 7.9% with 50.5%; plain phentermine 5.5% to 6.1%
One practical point that’s real but honestly sourced: the once-a-week-versus-once-a-day convenience advantage comes from adherence research in diabetes, not from these weight trials. Still, anyone who’s forgotten a daily medication while packing lunchboxes knows one calendar reminder beats seven.
And on the “5 ways to boost your results” searches: there’s no hack list here. The trial evidence says dose, diabetes status, and support move the number. That’s the list.
Can you lose 10 pounds in a week? The reality check
No. The trial math shows why: at roughly 0.2 to 0.3% of body weight per week, 10 lb in a week, or 20 lb in two months, isn’t what the evidence supports for most people. And that fast early drop people post about? Often water weight anyway.
Here’s the trap, and I’ve watched friends fall into it: measuring one week’s scale reading against a 68-week average is a category error. It’s like judging a marathon by your first block. The drug didn’t change; the denominator did.
Remember that distribution: about one in seven people never hit even 5% over 68 weeks. So if the scale is being stubborn, the question isn’t “why am I failing,” it’s where am I on my own curve.
And the bar that actually matters clinically is 5% of body weight. That’s the minimum shown to help, and 10% adds more benefit. Losing weight in that range improves blood sugar, cholesterol, and blood pressure. Modest numbers, real payoff.
Side effects that can distort the scale during the loss phase
The most common side effects are stomach and gut issues: nausea, vomiting, diarrhea, constipation. They’re usually mild and temporary. Severe ones can dehydrate you, though, that stalls honest fat loss and stresses your kidneys. And yeah, this part can just suck. There’s no hack for it.
The two-year numbers: about 82% of the drug group had some gut thing versus 54% on placebo. Mostly mild-to-moderate, mostly temporary, and only a small percentage of people quit over it. But “very common” is the honest label.
The rarer stuff, calmly: pancreatitis was very rare (0 to 0.2% across the trials). Gallbladder issues ran slightly higher on the drug than placebo. Heart rate ticked up 1 to 4 beats per minute on average, which is a footnote, not a headline. Low blood sugar is uncommon unless you’re also on insulin or similar.
The thyroid warning, explained simply: rodent studies found thyroid C-cell tumors, and that finding is what triggered the contraindications for medullary thyroid cancer (MTC) and MEN 2. There’s no established causation in humans, but it’s the reason people with certain thyroid histories can’t take the drug (full list next section).
Two practical notes. Keep fluids up, and reach out to your doctor if you can’t keep anything down. And on drug interactions: there are few known clashes with common medications, including metformin, which was tested directly along with several others. The theoretical concern that slower digestion might slow absorption of other pills didn’t show up as a real problem in testing. Your pharmacist can double-check your specific list.
Do you qualify for weight loss injections?
The FDA threshold is BMI 30 or higher, or 27 or higher with a weight-related condition such as hypertension, type 2 diabetes, or high cholesterol. BMI, quickly, is your weight relative to your height, one number your doctor can calculate in seconds.
Three situations rule the drug out entirely.
- A personal or family history of medullary thyroid cancer, a specific type of thyroid cancer
- MEN 2, a rare genetic syndrome affecting certain hormone glands
- A serious allergic response to the drug or any of its ingredients
Now the money, the part nobody warns you about. The sticker price was around $1,349 a month as of the 2022 source data, and I want to flag that’s stale; check current costs, because they’ve moved. Manufacturer coupons and assistance programs exist, including a Medicare option at about $50 a month for qualifying older adults, worth knowing if that’s you or your parents. And older generic meds cost a fraction of all this, which is honestly why many people land there. No judgment.
Cost check: Trial numbers only hold if you can stay on treatment. Sticker prices have moved since 2022, so check current costs and coupon programs before committing.
A couple of loose ends worth one line each. Older obesity guidelines don’t mention this drug because they predate it; that’s paperwork lag, not a red flag. And the big question about heart-health outcomes, tested in the SELECT trial of people with cardiovascular disease and overweight or obesity, showed the drug can carry cardiovascular benefit beyond the scale, which is part of why the qualifying conditions look the way they do.
But here’s the real point about cost: it’s the continuity constraint. All those trial numbers only apply if you can stay on treatment. The math doesn’t work if you can’t afford month seven.
What to track besides the scale each week
A slow scale week can still be a successful week, and the two-year trial data gives you a second scoreboard. From STEP 5: waist down about 9 cm (nearly 4 inches) on average, blood pressure down slightly, and blood sugar and cholesterol improved too.
In the STEP 5 exploratory analysis, 79.7% of people who started the two-year trial with prediabetes reverted to normoglycemia, versus 37.0% on placebo. Even trial-level averages, that one’s worth underlining.
Practical stuff you control: protect muscle with adequate protein and some resistance work, and keep movement going in whatever chunks your week allows. The scale measures one thing. It’s not the only scoreboard.
How injections compare to surgery and the next generation of drugs
Surgery still produces the biggest average losses: 20 to 25% at a year, with gastric bypass around 31%. The types, named plainly: gastric bypass, sleeve gastrectomy, and gastric banding. Surgery is a bigger undertaking too, typically months of counseling and readiness requirements at an accredited Metabolic and Bariatric Surgery Center of Excellence, a designation that signals the program meets audited safety and volume standards.
The evidence ladder, labeled honestly:
- Semaglutide: ~15%, peer-reviewed over 68 weeks
- Tirzepatide: ~20% average
- Retatrutide: ~30% in company-reported results, with notable dropouts from side effects at the highest dose. Not approved, and likely not available for years.
So the newer drugs are closing the gap with surgery, but they aren’t fully here, and the pipeline is a “what’s coming,” never a “wait for that instead.” It’s a framing echoed by endocrinologist Dr. Cecilia Low Wang of UCHealth, in coverage by Katie Kerwin McCrimmon, who has emphasized that these medications are meaningful tools but not automatic surgery replacements. And for anyone wondering whether tirzepatide beats semaglutide: the averages say yes, roughly 20% versus 15%, though they come from different trials, so the comparison carries a caveat.
Surgery isn’t ruled out by any of this. It’s information, not a referral.
Roughly 0.2% of your body weight a week once you’re at the full dose, on a curve that ramps slowly through week 16, moves fastest in the middle, plateaus around week 60, and reverses if you stop. That’s the honest answer to the headline question. Judge yourself against the curve and the 5% bar, not against “15%!” or anyone else’s week. That’s the whole mission here at Tidbits of Experience, taking life’s numbers and making them usable.
This is general information, not medical advice. Your clinician conversation comes first.
People Also ask
Why is my weight loss slowing down or stalling on Wegovy?
A plateau around week 60 is the treatment working, not failing — the trial curve levels off there and holds. Week-to-week loss is also not linear: some weeks will be zero and some will surprise you. About one in seven people never hit even 5% over 68 weeks, so a stubborn scale doesn’t mean you’re broken.
Wegovy vs Ozempic vs Zepbound: which injection causes the fastest weight loss?
Tirzepatide (Zepbound/Mounjaro) averages around 20% body weight loss versus roughly 15% for Wegovy over 68 weeks, though those numbers come from separate trials so the comparison carries a caveat. Ozempic is the same drug as Wegovy at a lower diabetes dose (1.0 mg), which produced only about 7% loss. Wegovy’s higher 7.2 mg dose showed about 19% in a manufacturer-reported 72-week study.
What factors affect how much weight you lose on GLP-1 injections?
Three things move your number: diabetes status, dose, and lifestyle support. The same drug averaged 9.6% in people with type 2 diabetes, 14.9% in the main trial, and 16.0% when stacked on intensive diet and exercise support. Diet and exercise changes were required in every trial arm, including placebo groups — the drug works alongside them, not instead of them.
What happens if I stop taking Wegovy?
In the withdrawal trial, people who stopped regained about 7% of their body weight, while those who kept taking it lost another 8% during the same stretch. That’s why doctors treat obesity as a chronic condition, like high blood pressure — the trial numbers only hold if you stay on treatment.
